Biogen's entry into hemophilia market caps a 'long journey' for patients
June 13, 2014 at 14:38 PM EDT
The approval this week of Biogen Idec’s second hemophilia drug cements the biotech’s entry into a disease field that has seen its share of setbacks in recent years...
